GSK and Fleming Initiative scientists unite to target AMR with advanced AI
Imperial wins Outstanding Entrepreneurial University at THE Awards
Imperial celebrates impact of supporters who gave £77.5 million in 2024-25
CDDS researchers work across a wide range of diseases, from infection and inflammation to oncology, cardiovascular disease and neurodegeneration.
View our network of disease experts
The CDDS brings together expertise in new screening technologies, target deconvolution, ultrasensitive biomarker analysis, microfluidic devices, and more.
View technology areas
We are developing small molecule, peptide, biological and cell-based modalities across a wide range of target classes and novel modes of action.
View target classes